BR112021025810A2 - Compostos radiomarcados direcionando o antígeno de membrana específico da próstata - Google Patents

Compostos radiomarcados direcionando o antígeno de membrana específico da próstata

Info

Publication number
BR112021025810A2
BR112021025810A2 BR112021025810A BR112021025810A BR112021025810A2 BR 112021025810 A2 BR112021025810 A2 BR 112021025810A2 BR 112021025810 A BR112021025810 A BR 112021025810A BR 112021025810 A BR112021025810 A BR 112021025810A BR 112021025810 A2 BR112021025810 A2 BR 112021025810A2
Authority
BR
Brazil
Prior art keywords
specific membrane
membrane antigen
radiolabeled compounds
prostate
compounds targeting
Prior art date
Application number
BR112021025810A
Other languages
English (en)
Inventor
David Perrin
François Bénard
Hsiou-Ting Kuo
Kuo-Shyan Lin
Zhengxing Zhang
Original Assignee
Provincial Health Services Authority
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincial Health Services Authority, Univ British Columbia filed Critical Provincial Health Services Authority
Publication of BR112021025810A2 publication Critical patent/BR112021025810A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Abstract

compostos radiomarcados direcionando antígeno de membrana específico da próstata.a presente invenção refere-se a um composto que compreende uma porção direcionada a antígeno de membrana específico da próstata (psma) da seguinte fórmula ou um sal ou um solvato da mesma. r0 é o ou s. cada um de r1a, r1b e r1c pode ser co2h, -so2h, -so3h, -po2h, ou- po3h2, por exemplo. r2 pode ser metileno ou um derivado do mesmo, propileno ou um derivado do mesmo, ou um derivado do etileno, opcionalmente substituído. r3 é um ligante. quando a porção de direcionamento de psma está ligada a um grupo de radiomarca-ção, o composto pode ser usado como um agente de imageamento ou agente terapêutico para doenças/condições expressando psma.
BR112021025810A 2019-06-21 2020-06-19 Compostos radiomarcados direcionando o antígeno de membrana específico da próstata BR112021025810A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865088P 2019-06-21 2019-06-21
US202063006643P 2020-04-07 2020-04-07
PCT/CA2020/050864 WO2020252598A1 (en) 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen

Publications (1)

Publication Number Publication Date
BR112021025810A2 true BR112021025810A2 (pt) 2022-05-10

Family

ID=74036930

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025810A BR112021025810A2 (pt) 2019-06-21 2020-06-19 Compostos radiomarcados direcionando o antígeno de membrana específico da próstata

Country Status (10)

Country Link
US (2) US11504441B2 (pt)
EP (1) EP3986872A4 (pt)
JP (1) JP2022537773A (pt)
KR (1) KR20220024595A (pt)
CN (1) CN114401947A (pt)
AU (1) AU2020296488A1 (pt)
BR (1) BR112021025810A2 (pt)
CA (1) CA3144094A1 (pt)
IL (1) IL288960A (pt)
WO (1) WO2020252598A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240018110A1 (en) * 2020-12-16 2024-01-18 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
TW202321204A (zh) * 2021-11-10 2023-06-01 大陸商蘇州瑞核醫藥科技有限公司 靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用
WO2023164775A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority Radiolabeled compounds targetng the prostate-specific membrane antigen
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
WO2024016071A1 (en) * 2022-07-18 2024-01-25 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
CN117045828A (zh) * 2023-10-12 2023-11-14 北京先通国际医药科技股份有限公司 212Pb标记的放射性化合物在制备治疗前列腺癌药物中的用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US7563433B2 (en) 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
EP2581382A2 (en) 2004-02-13 2013-04-17 The University Of British Columbia Radiolabeled compounds and compositions, their precursors and methods for their production
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
WO2008058192A2 (en) 2006-11-08 2008-05-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US9044468B2 (en) 2007-06-26 2015-06-02 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
CA2731645C (en) 2007-07-24 2017-05-23 The University Of British Columbia Substituted aryl-fluoroborates as imaging agents
CN102171187B (zh) 2008-08-01 2017-07-28 约翰.霍普金斯大学 Psma‑结合剂及其用途
WO2012094334A1 (en) 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
WO2012118909A1 (en) 2011-03-01 2012-09-07 Ge Healthcare Limited Radiolabelled octreotate analogues as pet tracers
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
WO2014078484A1 (en) 2012-11-15 2014-05-22 Endocyte, Inc. Conjugates for treating diseases caused by psma expressing cells
US20140147381A1 (en) 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
EP2964658A4 (en) 2013-03-08 2016-11-02 Univ British Columbia SUBSTITUTED ORGANOFLUOROBORATES AS IMAGING AGENTS
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
EP3777898A3 (en) 2013-11-14 2021-04-21 Endocyte, Inc. Compounds for positron emission tomography
CA2972058C (en) 2014-01-03 2022-05-24 British Columbia Cancer Agency Branch Compositions and methods for imaging cancer
WO2015135082A1 (en) 2014-03-13 2015-09-17 British Columbia Cancer Agency Branch Bradykinin receptor b1 targeting probes
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
WO2017117687A1 (en) 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen
BR112019010206A2 (pt) 2016-11-23 2019-09-03 Cancer Targeted Tech Llc composto, composição farmacêutica, e, método para formar imagem de uma ou mais células cancerígenas de próstata
CN106967152B (zh) 2017-03-28 2019-11-26 江苏省原子医学研究所 一种氟-18标记的化合物及其制备方法与应用
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
US10975089B2 (en) * 2017-06-06 2021-04-13 Clarity Pharmaceuticals Ltd Radiopharmaceuticals, radioimaging agents, and uses thereof
US20200339625A1 (en) 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US11497819B2 (en) 2017-12-11 2022-11-15 Technische Universität München PSMA ligands for imaging and endoradiotherapy
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
CN112770785A (zh) 2018-09-28 2021-05-07 海德堡大学 前列腺特异性膜抗原(psma)的标记抑制剂，其作为显像剂和药剂用于治疗表达psma的癌症的用途
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
US20220062446A1 (en) 2018-12-18 2022-03-03 Provincial Health Services Authority Dual mode 18f-labelled theranostic compounds and uses thereof

Also Published As

Publication number Publication date
KR20220024595A (ko) 2022-03-03
US20230114807A1 (en) 2023-04-13
EP3986872A4 (en) 2024-02-21
CN114401947A (zh) 2022-04-26
CA3144094A1 (en) 2020-12-24
US11504441B2 (en) 2022-11-22
EP3986872A1 (en) 2022-04-27
WO2020252598A1 (en) 2020-12-24
US20210338851A1 (en) 2021-11-04
IL288960A (en) 2022-02-01
AU2020296488A1 (en) 2022-01-20
JP2022537773A (ja) 2022-08-29

Similar Documents

Publication Publication Date Title
BR112021025810A2 (pt) Compostos radiomarcados direcionando o antígeno de membrana específico da próstata
MA50667A (fr) Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif
BR112015013611A2 (pt) composto, e, composição farmacêutica
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112015028212A2 (pt) derivado de fenol e método de preparação e utilização dos mesmos na medicina
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BRPI0821855B8 (pt) composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
BR112022011123A2 (pt) Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
BR112018074632A2 (pt) combinações compreendendo inibidores de histona desacetilase
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
EA201890221A1 (ru) Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов
BR112017005299A2 (pt) inibidores de lrrk2 cinase macrocíclicos
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112019007145A2 (pt) combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
BR112022010323A2 (pt) Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
BR112021011325A2 (pt) Derivados de rapamicina